Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 10,730 matching trials from the live ClinicalTrials.gov search.
Conditions
Waldenstrom Macroglobulinemia
Interventions
Epratuzumab (hLL2- anti-CD22 humanized antibody)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Radiation
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma
Interventions
Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
Interventions
Daratumumab
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
16
States / cities
Phoeniz, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Conditions
Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Interventions
Acalabrutinib, Investigator's choice of treatment
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Arginine Therapy for Sickle Cell Disease Pain

NCT02536170
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions
L-arginine, L-arginine Loading Dose, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
3 Years to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Venous Thromboembolism, Multiple Myeloma
Interventions
Apixaban
Drug
Lead sponsor
Gregory Piazza
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Obinutuzumab, Corticosteroids
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 24 more
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cladribine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Venetoclax
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
sargramostim, mitomycin C, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Obinutuzumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency
Interventions
Immunoglobulins Intravenous (Human)
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
4 Years to 71 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 7 more
Conditions
Multiple Myeloma, Lymphoma
Interventions
Resistant Starch, Maltodextrin
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Not applicable Interventional Accepts healthy volunteers Results available

Heel Wedges and Carbon Fiber Custom Dynamic Orthoses to Control Knee Biomechanics

NCT05209360
Conditions
Adult ALL, Healthy
Interventions
Medial or Lateral Wedge, Carbon Fiber Custom Dynamic Orthosis
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
venetoclax, azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 6 more
Not listed No phase listed Observational Accepts healthy volunteers

Project Baseline Health Study

NCT03154346
Conditions
All
Interventions
Not listed
Lead sponsor
Baseline Study LLC
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
5
States / cities
South San Francisco, California • Stanford, California • Westlake Village, California + 2 more
Conditions
Relapsed Refractory Multiple Myeloma
Interventions
Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more
Conditions
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions
Posaconazole, ABT-199, Decitabine, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
13
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Imatinib, Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
21
States / cities
Anaheim, California • Fontana, California • Los Angeles, California + 18 more
Conditions
Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies, Disorder Related to Transplantation
Interventions
GM-CSF, Rituximab, NK Cell Infusion
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 2 Interventional Results available

Obatoclax for Systemic Mastocytosis

NCT00918931
Conditions
Leukemia, Systemic Mastocytosis
Interventions
Obatoclax Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Leukemia, Childhood Acute Leukemia of Ambiguous Lineage, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration, Revumenib
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Lymphoid Leukemia
Interventions
Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR), Treg CD34+HSPC (Orca-T)
Drug
Lead sponsor
Melody Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Multiple Myeloma, Amyloidosis
Interventions
DaraVRD/DaraVCD
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama